SBIR/STTR Research Award

Oral Enzymatic Management of Phenylketonuria

Award identifier 8c74d42cdc438fd54576e9ff9de471488c1a65f05df50c740bdb5e2bc6f1147dAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$225,000

Program and phase

STTR · Phase I

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ABRI SCIENCE, LLC
Proposal award date
2019-09-17
Contract end date
2020-08-31
UEI
CMPRHZJGJ3H1
Solicitation number
PA18-575
Topic code
300

Research abstract

PhenylketonuriaPKUis a genetic disorder of metabolism characterized by a pathological elevation of phenylalaninePhein the body stemming from a dysfunctional phenylalanine hydroxylase enzymePAHThe resulting high concentrations of Phexcan result in severe intellectual disabilitybehavioral problemsand neurological deficitse gseizuresStrict control of dietary Phe is the primary treatment for PKU current guidelines require diet therapy to be continued for lifewhich markedly exacerbates the problem of non complianceespecially in older children and adultsAn alternative treatment for PKU involves thereplacementof the endogenous PAH with a different Phe metabolizing enzyme such as phenylalanine ammonia lyasePALOrally administered PAL reduced plasma Phe levelsbut this effect was transient as the destruction of PAL by harsh environment of the gastrointestinal tractg i tnecessitated huge doses of the enzymeWe have designed a novel technology to reduce dietary Phe levels in the g i tby oral administration of microencapsulated PALPreliminary studies have demonstrated that we can successfully encapsulate PALPALEin ethyl cellulose using a patented emulsion dispersion techniqueHoweverPALE exhibitsof the activity of unencapsulated enzymePALUin solution limiting its implementation in its current formThe goal of this proposal is to optimize the formulation parameters to encapsulate PAL and characterize its properties in vitro enabling future development efforts Phenylketonuria is an inborn error of metabolismcharacterized by mutations in the enzyme phenylalanine hydroxylase causing a pathological elevation of phenylalanine in the bloodOrally active enzyme replacement therapy has shown initial promise but limited efficacy as native processes break down the exogenous enzymes resulting in a transient reduction in phenylalanine levelsMicroencapsulation of enzymes in a porous and non toxic membrane represents an innovative way to prolong stability and functionality in the destructive environment of the gastrointestinal tract and has the potential to help alleviate the enormous burden experienced by patients

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.